The new cell input trail improves the effects of gene therapy

Scientists at the Centenary Institute and the University of Sydney have made a milestone discovery that could lead to safer and more effective gene therapies for a series of serious genetic disorders, such as Duchenne muscular dystrophy, Pompe disease.

Published in the top magazine CellThe study identifies a previous unknown gateway to human cells, a receptor called AAVR2, used by gene therapy viruses to provide therapeutic genes. This recently unsecured pathway could allow the use of lower doses of the virus in treatment, helping to reduce the side effects and costs of treatment, improving the results of patients.

Gene therapies use typically modified viruses, known as AVS -related viruses to provide healthy genes to the body. These treatments have the ability to change life for patients, their families and their carers. However, they often require high doses of carrier to achieve therapeutic effects, which in some cases can cause severe immunocommals, lead to serious complications or even death.

“We have found that some types of AAVs can use this recently recognized receptor, AAVR2, to enter cells, providing an alternative to the previously known input route,” said Dr. Bijay Dhungel, head of the study and researcher at the Center for Disease Center.

This discovery reveals a completely new path to gene delivery to cells. The formation of this route can potentially make gene therapies safer, cheaper and more accurate. ”

Dr. Bijay Dhungel, Center for Rare Diseases & Genetic Therapy, Centenary Institute

Using advanced techniques of genetics, biochemistry and molecular biology, researchers have shown that AAVR2 plays a critical role in providing aid to several types of AAVs, including widely used in patients, more efficiently enter cells.

“We not only found this new AAVR2 receptor, but we also discovered how it is bound by the viruses provided by genes,” said co-symbatriotis Dr Charles (Chuck) Bailey, head of the Center of Rare Diseases and General Therapy at Centenary Institute.

“Then we went one step further and designed a tiny version of the receptor and proved that this greatly enhances how effectively gene therapy is obtained in human cells and tissues.

Researchers say the findings have a significant impact on the future of gene therapy, offering new strategies to adapt therapies, the lowest required doses and possibly avoid the complications associated with the immune system that have limited certain current approaches.

The discovery also promotes a scientific understanding of how therapeutic viruses interact with human cells. These are basic knowledge of the development of the next generation of safe, effective and guided gene remedies.

The study was supported by funding by the New South Wales Health, National Health and Medical Research Council (NHMRC), Australia, Tour De Cure, Cure the Future and Brandon Capital Coxetor.